Katriana Nugent
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Katriana Nugent has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Phuoc T. Tran
The University of Texas MD Anderson Cancer Center 4 , Houston, Texas
19 shared publications - Hailun Wang
BGI-shenzhen, Shenzhen, China
17 shared publications - Kekoa Taparra
Department of Health Policy and Management UCLA Fielding School of Public Health Los Angeles California USA
15 shared publications - Reem Malek
Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD
15 shared publications - Aaron Chan
Division of Translational Radiation Sciences, Department of Radiation Oncology, University of Maryland Baltimore, School of Medicine, Baltimore, Maryland
14 shared publications - Andrew Jon Holland
Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine
14 shared publications
Latest Publications
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Griseofulvin Radiosensitizes Non–Small Cell Lung Cancer Cells and Activates cGAS
Figure S1 shows basal centrosome amplification in cell lines. Figure S2 shows the effect of GF on cell viability. Figure S3 shows HSET expression in cell lines. Figure S4 shows the effect of GF on clonogenic potential after RT. Figure S5 shows the induction of micronuclei after GF and/or RT. Figure S6 shows the expression of IFN-β after GF and/or RT.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Griseofulvin Radiosensitizes Non–Small Cell Lung Cancer Cells and Activates cGAS
Figure S1 shows basal centrosome amplification in cell lines. Figure S2 shows the effect of GF on cell viability. Figure S3 shows HSET expression in cell lines. Figure S4 shows the effect of GF on clonogenic potential after RT. Figure S5 shows the induction of micronuclei after GF and/or RT. Figure S6 shows the expression of IFN-β after GF and/or RT.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Materials & Methods from Griseofulvin Radiosensitizes Non–Small Cell Lung Cancer Cells and Activates cGAS
Supplementary Materials & Methods
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials & Methods from Griseofulvin Radiosensitizes Non–Small Cell Lung Cancer Cells and Activates cGAS
Supplementary Materials & Methods
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Materials & Methods from Griseofulvin Radiosensitizes Non–Small Cell Lung Cancer Cells and Activates cGAS
Supplementary Materials & Methods
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials & Methods from Griseofulvin Radiosensitizes Non–Small Cell Lung Cancer Cells and Activates cGAS
Supplementary Materials & Methods
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Griseofulvin Radiosensitizes Non–Small Cell Lung Cancer Cells and Activates cGAS
Figure S1 shows basal centrosome amplification in cell lines. Figure S2 shows the effect of GF on cell viability. Figure S3 shows HSET expression in cell lines. Figure S4 shows the effect of GF on clonogenic potential after RT. Figure S5 shows the induction of micronuclei after GF and/or RT. Figure S6 shows the expression of IFN-β after GF and/or RT.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Griseofulvin Radiosensitizes Non–Small Cell Lung Cancer Cells and Activates cGAS
Figure S1 shows basal centrosome amplification in cell lines. Figure S2 shows the effect of GF on cell viability. Figure S3 shows HSET expression in cell lines. Figure S4 shows the effect of GF on clonogenic potential after RT. Figure S5 shows the induction of micronuclei after GF and/or RT. Figure S6 shows the expression of IFN-β after GF and/or RT.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Griseofulvin Radiosensitizes Non–Small Cell Lung Cancer Cells and Activates cGAS
Extra copies of centrosomes are frequently observed in cancer cells. To survive and proliferate, cancer cells have developed strategies to cluster extra-centrosomes to form bipolar mitotic spindles. The aim of this study was to investigate whether centrosome clustering (CC) inhibition (CCi) would preferentially radiosensitize non–small cell lung cancer (NSCLC). Griseofulvin (GF; FDA-approved treatment) inhibits CC, and combined with radiation treatment (RT), resulted in a significant increase in the number of NSCLC cells with multipolar spindles, and decreased cell viability and colony formation ability in vitro. In vivo, GF treatment was well tolerated by mice, and the combined therapy of GF and radiation treatment resulted in a significant tumor growth delay. Both GF and radiation treatment also induced the generation of micronuclei (MN) in vitro and in vivo and activated cyclic GMP-AMP synthase (cGAS) in NSCLC cells. A significant increase in downstream cGAS-STING pathway activation was seen after combination treatment in A549 radioresistant cells that was dependent on cGAS. In conclusion, GF increased radiation treatment efficacy in lung cancer preclinical models in vitro and in vivo. This effect may be associated with the generation of MN and the activation of cGAS. These data suggest that the combination therapy of CCi, radiation treatment, and immunotherapy could be a promising strategy to treat NSCLC.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Griseofulvin Radiosensitizes Non–Small Cell Lung Cancer Cells and Activates cGAS
Extra copies of centrosomes are frequently observed in cancer cells. To survive and proliferate, cancer cells have developed strategies to cluster extra-centrosomes to form bipolar mitotic spindles. The aim of this study was to investigate whether centrosome clustering (CC) inhibition (CCi) would preferentially radiosensitize non–small cell lung cancer (NSCLC). Griseofulvin (GF; FDA-approved treatment) inhibits CC, and combined with radiation treatment (RT), resulted in a significant increase in the number of NSCLC cells with multipolar spindles, and decreased cell viability and colony formation ability in vitro. In vivo, GF treatment was well tolerated by mice, and the combined therapy of GF and radiation treatment resulted in a significant tumor growth delay. Both GF and radiation treatment also induced the generation of micronuclei (MN) in vitro and in vivo and activated cyclic GMP-AMP synthase (cGAS) in NSCLC cells. A significant increase in downstream cGAS-STING pathway activation was seen after combination treatment in A549 radioresistant cells that was dependent on cGAS. In conclusion, GF increased radiation treatment efficacy in lung cancer preclinical models in vitro and in vivo. This effect may be associated with the generation of MN and the activation of cGAS. These data suggest that the combination therapy of CCi, radiation treatment, and immunotherapy could be a promising strategy to treat NSCLC.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Griseofulvin Radiosensitizes Non–Small Cell Lung Cancer Cells and Activates cGAS
Figure S1 shows basal centrosome amplification in cell lines. Figure S2 shows the effect of GF on cell viability. Figure S3 shows HSET expression in cell lines. Figure S4 shows the effect of GF on clonogenic potential after RT. Figure S5 shows the induction of micronuclei after GF and/or RT. Figure S6 shows the expression of IFN-β after GF and/or RT.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Griseofulvin Radiosensitizes Non–Small Cell Lung Cancer Cells and Activates cGAS
Figure S1 shows basal centrosome amplification in cell lines. Figure S2 shows the effect of GF on cell viability. Figure S3 shows HSET expression in cell lines. Figure S4 shows the effect of GF on clonogenic potential after RT. Figure S5 shows the induction of micronuclei after GF and/or RT. Figure S6 shows the expression of IFN-β after GF and/or RT.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Griseofulvin Radiosensitizes Non–Small Cell Lung Cancer Cells and Activates cGAS
Extra copies of centrosomes are frequently observed in cancer cells. To survive and proliferate, cancer cells have developed strategies to cluster extra-centrosomes to form bipolar mitotic spindles. The aim of this study was to investigate whether centrosome clustering (CC) inhibition (CCi) would preferentially radiosensitize non–small cell lung cancer (NSCLC). Griseofulvin (GF; FDA-approved treatment) inhibits CC, and combined with radiation treatment (RT), resulted in a significant increase in the number of NSCLC cells with multipolar spindles, and decreased cell viability and colony formation ability in vitro. In vivo, GF treatment was well tolerated by mice, and the combined therapy of GF and radiation treatment resulted in a significant tumor growth delay. Both GF and radiation treatment also induced the generation of micronuclei (MN) in vitro and in vivo and activated cyclic GMP-AMP synthase (cGAS) in NSCLC cells. A significant increase in downstream cGAS-STING pathway activation was seen after combination treatment in A549 radioresistant cells that was dependent on cGAS. In conclusion, GF increased radiation treatment efficacy in lung cancer preclinical models in vitro and in vivo. This effect may be associated with the generation of MN and the activation of cGAS. These data suggest that the combination therapy of CCi, radiation treatment, and immunotherapy could be a promising strategy to treat NSCLC.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Griseofulvin Radiosensitizes Non–Small Cell Lung Cancer Cells and Activates cGAS
Extra copies of centrosomes are frequently observed in cancer cells. To survive and proliferate, cancer cells have developed strategies to cluster extra-centrosomes to form bipolar mitotic spindles. The aim of this study was to investigate whether centrosome clustering (CC) inhibition (CCi) would preferentially radiosensitize non–small cell lung cancer (NSCLC). Griseofulvin (GF; FDA-approved treatment) inhibits CC, and combined with radiation treatment (RT), resulted in a significant increase in the number of NSCLC cells with multipolar spindles, and decreased cell viability and colony formation ability in vitro. In vivo, GF treatment was well tolerated by mice, and the combined therapy of GF and radiation treatment resulted in a significant tumor growth delay. Both GF and radiation treatment also induced the generation of micronuclei (MN) in vitro and in vivo and activated cyclic GMP-AMP synthase (cGAS) in NSCLC cells. A significant increase in downstream cGAS-STING pathway activation was seen after combination treatment in A549 radioresistant cells that was dependent on cGAS. In conclusion, GF increased radiation treatment efficacy in lung cancer preclinical models in vitro and in vivo. This effect may be associated with the generation of MN and the activation of cGAS. These data suggest that the combination therapy of CCi, radiation treatment, and immunotherapy could be a promising strategy to treat NSCLC.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Materials & Methods from Griseofulvin Radiosensitizes Non–Small Cell Lung Cancer Cells and Activates cGAS
Supplementary Materials & Methods
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials & Methods from Griseofulvin Radiosensitizes Non–Small Cell Lung Cancer Cells and Activates cGAS
Supplementary Materials & Methods
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer
Supplementary Figure legends and methods
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer
Supplementary Figure legends and methods
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Griseofulvin Radiosensitizes Non–Small Cell Lung Cancer Cells and Activates cGAS
Figure S1 shows basal centrosome amplification in cell lines. Figure S2 shows the effect of GF on cell viability. Figure S3 shows HSET expression in cell lines. Figure S4 shows the effect of GF on clonogenic potential after RT. Figure S5 shows the induction of micronuclei after GF and/or RT. Figure S6 shows the expression of IFN-β after GF and/or RT.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Griseofulvin Radiosensitizes Non–Small Cell Lung Cancer Cells and Activates cGAS
Figure S1 shows basal centrosome amplification in cell lines. Figure S2 shows the effect of GF on cell viability. Figure S3 shows HSET expression in cell lines. Figure S4 shows the effect of GF on clonogenic potential after RT. Figure S5 shows the induction of micronuclei after GF and/or RT. Figure S6 shows the expression of IFN-β after GF and/or RT.